Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Kazia

What Sparked Kazia Therapeutics' Over 51% After-Hours Surge?

Kazia Therapeutics Limited (NASDAQ:KZIA) shares are trending on Wednesday.

Benzinga · Nov 19, 2025

Oncology company reports promising cancer find

Shares in Kazia Therapeutics have risen more than 50 per cent after its drug candidate appeared to successfully treat a woman with stage-four breast cancer.

AAP · Nov 19, 2025

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Aug 5, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Aug 1, 2022

Kazia Shares Shoot Higher As FDA Grants Rare Pediatric Disease Designation To Brain Cancer Candidate

The United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia Therapeutics’ (NASDAQ: KZIA) lead drug Paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT).

Benzinga · Jul 6, 2022

Kazia Therapeutics' Shares Gain Following FDA Orphan Drug Status For Childhood Brain Cancer Drug

The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kazia Therapeutics’ (NASDAQ: KZIA) Paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly-aggressive childhood brain cancer.

Benzinga · Jun 17, 2022

Kazia Therapeutics Concludes Mid-Stage Paxalisib Study In Brain Cancer

Kazia Therapeutics Limited (NASDAQ: KZIA) has completed a Phase 2 study of paxalisib in glioblastoma.

Benzinga · Apr 21, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

423,742 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.